Business
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners ConferenceCompany plans to file its Earnings Report on May 20, 2026 on Form 10-Q for the quarter ended March 31, 2026 SAN FRANCISCO, CA / ACCESS Newswire / May 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 26, 2026 at 8:30 a.m. Eastern to review first-quarter 2026 financials and provide corporate updates, and that Lisa Conte, Jaguar's founder, president and CEO, will present virtually on Thursday, May 28, 2026 at 10 a.m. Eastern at the Lytham Partners Spring 2026 Investor Conference.Participation Instructions for Jaguar Health Investor WebcastWhen: Tuesday, May 26, 2026 at 8:30 a.m. EasternParticipant Registration & Access Link: Click HereReplay: A replay of the webcast will be available on the investor relations section of Jaguar's website: (click here)Participation Instructions for Jaguar's Virtual Presentation at the Lytham Partners Spring 2026 Investor ConferenceWhen: Thursday, May 28, 2026 at 10 a.m. EasternRegistration link for conference: Click HereReplay: A replay of the webcast will be available through the same link (click here)About the Jaguar Health Family of CompaniesJaguar Health, Inc. (\"Jaguar\") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (\"GI\") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit https://jaguar.healthNapo Pharmaceuticals, visit napopharma.comNapo Therapeutics, visit napotherapeutics.comMagdalena Biosciences, visit magdalenabiosciences.comForward-Looking StatementsCertain statements in this press release constitute \"forward-looking...